0001209191-22-051370.txt : 20220927 0001209191-22-051370.hdr.sgml : 20220927 20220927164631 ACCESSION NUMBER: 0001209191-22-051370 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220923 FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Decheng Capital China Life Sciences USD Fund III, L.P. CENTRAL INDEX KEY: 0001736814 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 221271654 BUSINESS ADDRESS: STREET 1: UGLAND HOUSE, PO BOX 309 CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: 345-949-8066 MAIL ADDRESS: STREET 1: UGLAND HOUSE, PO BOX 309 CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Decheng Capital Management III (Cayman), LLC CENTRAL INDEX KEY: 0001747821 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 221271653 BUSINESS ADDRESS: STREET 1: PO BOX 309 STREET 2: UGLAND HOUSE CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: 345-949-8066 MAIL ADDRESS: STREET 1: PO BOX 309 STREET 2: UGLAND HOUSE CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-23 0 0001626199 ALPINE IMMUNE SCIENCES, INC. ALPN 0001736814 Decheng Capital China Life Sciences USD Fund III, L.P. UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104 CAYMAN ISLANDS 0 0 1 0 0001747821 Decheng Capital Management III (Cayman), LLC UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104 CAYMAN ISLANDS 0 0 1 0 Common Stock 2022-09-23 4 A 0 639456 7.35 A 5347744 D Common Stock 2022-09-23 4 A 0 1360544 7.35 A 1360544 I See footnote The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports. The reportable securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healtchcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare, Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Healthcare GP disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports. Decheng Capital China Life Sciences USD Fund III, L.P., By Decheng Capital Management III (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager 2022-09-27 Decheng Capital Management III (Cayman), LLC, By /s/ Xiangmin Cui, Manager 2022-09-27